India caps 36 more drug prices; Pfizer puts $2M toward 'last-mile' vax coverage;

@FiercePharma: Top-read pharma news Thurs: Put a lid on 'Low-T' drug use, FDA panel advises, threatening AbbVie, Lilly meds. Story | Follow @FiercePharma

@EricPFierce: Potentially bad news for Amphastar and its $155.7M deal if Sanofi makes insulin for Mannkind. Story via FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Protein Sciences nabs stake in diabetes vax developer Diamyd. More from FierceVaccines | Follow @CarlyHFierce

> India has put price limits on three dozen more drugs. Story

> British health workers have voted for strike action over an NHS pay freeze. More

> Pfizer ($PFE) will provide $2 million to support 'last-mile' vaccine coverage. More

> Drugstore chain Rite Aid cut its earnings forecast to a range of 22 cents to 33 cents from 30 cents to 40 cents, saying it will be dampened by contracting margins on generic drugs. Report

Medical Device News

@FierceMedDev: UDI architect shares compliance tips on eve of regulation's first deadline. More | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of #polio vax application. Story | Follow @MichaelGFierce

@VarunSaxena2: Court ruling against FDA should enable more combination products to be classified as devices. Article | Follow @VarunSaxena2

@EmilyWFierce: San Francisco startup stirring up buzz for chicken egg facsimile, cataloging plant proteins to create new food model. Story | Follow @EmilyWFierce

> Apple HealthKit delayed by bug as major EHR players commit. Story

> British startup launches crowdfunding effort for 3-D printed orthotic devices. Article

Biotech News

@FierceBiotech: Cubist makes Euro landfall with a $400M purse for antibiotics R&D. More | Follow @FierceBiotech

@JohnCFierce: FYI, I'm setting up some meets after the executive panel in Boston next month. Details | Follow @JohnCFierce

@DamianFierce: The @FierceBiotech Fierce 15 unveiling is happening live (and live-streamed) on Monday in Boston at #BPA14. Story | Follow @DamianFierce

@EmilyMFierce: Antibiotics R&D to get critical lift by executive order, Obama advisory group. Article | Follow @EmilyMFierce

> French immuno-oncology biotech OSE eyes an EU IPO. Item

> Novo Nordisk wins EU approval for a diabetes combo with billion-dollar potential. More

> Merck KGaA rearranges its executive board amid biosimilar surge. Story

And Finally... What health issues will millennials face that their parents didn't? More (sub. req.)

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.